Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AlgoNomics has entered into research collaboration with Genmab that will allow the company to employ its antibody structure database and Tripole technology to assist in research related to the structural analysis of Genmab's proprietary antibody scaffolds, including the UniBody technology.
Subscribe to our email newsletter
Under the terms of the agreement, AlgoNomics is eligible for research funding and subsequent potential milestone payments from Genmab. The research collaboration focuses on the structural properties of fully human antibody and UniBody molecules.
Ignace Lasters, chief scientific officer of AlgoNomics, said: “Combining our structural perspective with the biological and clinical insights of their discovery and development teams may accelerate the development of Genmab’s UniBody technology.”